IFNA2 and myeloid sarcoma: It is noteworthy though that a preserved in vivo response to IFN-α has been observed in MS patients with neutralizing antibodies against interferon-beta and that IFN-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis (RRMS) (22).